HLA-A and neoplasm: Interestingly, and counterintuitively, tumours with loss of HLA-A and/or HLA-B expression demonstrated improved survival in this clinical trial, suggesting that treatment response to PD1 blockade is a complex process that goes beyond antigen presentation on MHC Class I and inhibiting tumour PDL1 interactions.